SkinCure Oncology, the industry leader in providing a comprehensive cancer center model for the delivery of Image-Guided Superficial Radiation Therapy (Image-Guided SRT or IGSRT) for the treatment of ...

Explore how a topical cream targets squamous cell carcinoma by enhancing immune responses in the skin for tumour suppression.

He had just been diagnosed with skin cancer on his lip. “As you can imagine, I was a bit off on the golf course after that,” he said. It was a Friday, back in the fall of 2024, and during that weekend ...

The state ranks 48th in the nation for primary care physicians per 100,000 residents, leaving many patients struggling to ...

Spots, bumps or patches that suddenly appear on your skin can be alarming, especially if they grow quickly, become red or irritated, or do not seem to heal. It can be difficult to tell whether it is ...

Similar to brachytherapy, OncoPatch could be an option for patients who have superficial lesions or who aren’t surgical candidates.

Get the Well Enough newsletter with Harry Bullmore for tips on living a healthier, happier and longer life Get the Well Enough email with Harry Bullmore When you’re waiting to learn whether or not you ...

FDA Priority Review was granted for trastuzumab deruxtecan in post-neoadjuvant HER2-positive early breast cancer with residual invasive disease, with a regulatory decision anticipated in Q3 2026.

In this Review, Saviano et al. explore the frequent deregulation of claudins (CLDNs) in solid tumours and highlight their role in cancer progression. They discuss strategies to target CLDNs by ...

A topical cream activated the skin's immune defenses and suppressed tumor growth in two preclinical models of cutaneous squamous cell carcinoma (cSCC), one of the most common cancers in the world, ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.